| Hypertriglyceridemia in Apoa5-/- mice results from reduced amounts of lipoprotein lipase in the capillary lumen. | Hypertriglyceridemia in Apoa5-/- mice results from reduced amounts of lipoprotein lipase in the capillary lumen.
Yang Y, Beigneux AP, Song W, Nguyen LP, Jung H, Tu Y, Weston TA, Tran CM, Xie K, Yu RG, Tran AP, Miyashita K, Nakajima K, Murakami M, Chen YQ, Zhen EY, Kim JR, Kim PH, Birrane G, Tontonoz P, Ploug M, Konrad RJ, Fong LG, Young SG., Free PMC Article | 01/31/2024 |
| Apolipoprotein A5 controls fructose-induced metabolic dysregulation in mice. | Apolipoprotein A5 controls fructose-induced metabolic dysregulation in mice.
Ress C, Dobner J, Rufinatscha K, Staels B, Hofer M, Folie S, Radlinger B, Adolph TE, Rubin EM, Roden M, Tilg H, Kaser S. | 03/20/2021 |
| Magnolol-mediated regulation of plasma triglyceride through affecting lipoprotein lipase activity in apolipoprotein A5 knock-in mice. | Magnolol-mediated regulation of plasma triglyceride through affecting lipoprotein lipase activity in apolipoprotein A5 knock-in mice.
Chang CK, Lin XR, Lin YL, Fang WH, Lin SW, Chang SY, Kao JT., Free PMC Article | 05/7/2019 |
| lnc-RAP3 suppress 3T3-L1 preadipocyte differentiation by affecting the expression of the genes involved in adipogenic differentiation. | [The effect of lnc-RAP3 on 3T3-L1 preadipocyte differentiation in mouse].
Li H, Feng JC, Li GL, Wang X, Li MZ, Liu HF. | 03/30/2019 |
| ApoA-V is a novel regulator of lipid metabolism in cardiomyocytes. | Effects and mechanisms of apolipoprotein A-V on the regulation of lipid accumulation in cardiomyocytes.
Luo J, Xu L, Li J, Zhao S., Free PMC Article | 09/22/2018 |
| novel role for ApoA5 as a modulator of susceptibility to diet-induced liver and muscle insulin resistance through regulation of ectopic lipid accumulation in liver and skeletal muscle. | ApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid content.
Camporez JPG, Kanda S, Petersen MC, Jornayvaz FR, Samuel VT, Bhanot S, Petersen KF, Jurczak MJ, Shulman GI., Free PMC Article | 11/21/2015 |
| The data suggest that apoA-V suppresses the production of chylomicrons, playing a previously unknown role in lipid metabolism that may contribute to the postprandial hypertriglyceridemia associated with apoA-V deficiency. | Apolipoprotein A-V deficiency enhances chylomicron production in lymph fistula mice.
Zhang LS, Xu M, Yang Q, Ryan RO, Howles P, Tso P., Free PMC Article | 06/6/2015 |
| Data indicate that apolipoprotein A5 (APOA5) plays a role in the central regulation of food intake. | Apolipoprotein A5 deficiency aggravates high-fat diet-induced obesity due to impaired central regulation of food intake.
van den Berg SA, Heemskerk MM, Geerling JJ, van Klinken JB, Schaap FG, Bijland S, Berbée JF, van Harmelen VJ, Pronk AC, Schreurs M, Havekes LM, Rensen PC, van Dijk KW. | 12/21/2013 |
| Clearance of triglyceride-rich lipoproteins by hepatic SDC1 is atheroprotective and mediated by multivalent binding to ApoE and ApoAV. | Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans.
Gonzales JC, Gordts PL, Foley EM, Esko JD., Free PMC Article | 08/3/2013 |
| Gene transfer of human apoA-V improves the severe hypertriglyceridemia phenotype of apoa5 null mice. | Gene transfer of apolipoprotein A-V improves the hypertriglyceridemic phenotype of apoa5 (-/-) mice.
Sharma V, Beckstead JA, Simonsen JB, Nelbach L, Watson G, Forte TM, Ryan RO., Free PMC Article | 04/13/2013 |
| Intravenously injected apoA-V rHDL significantly lowers plasma TG in an apoA-V deficient mouse model and requires gpihbp1. | Intravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav-/- mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1.
Shu X, Nelbach L, Weinstein MM, Burgess BL, Beckstead JA, Young SG, Ryan RO, Forte TM., Free PMC Article | 01/1/2011 |
| Data show that livers from apolipoprotein A-V (APOA-V) transgenic mice contain significantly higher amounts of triglycerides than livers from wild-type or apoA-V knockout mice, suggesting that apoA-V influences intrahepatic triglyceride levels. | Apolipoprotein A-V associates with intrahepatic lipid droplets and influences triglyceride accumulation.
Shu X, Nelbach L, Ryan RO, Forte TM., Free PMC Article | 05/31/2010 |
| Preferential association of apoA-V(1-146) with murine plasma HDL, but not with VLDL, suggests that particle size is a determinant of its lipoprotein binding specificity. | Apolipoprotein A-V N-terminal domain lipid interaction properties in vitro explain the hypertriglyceridemic phenotype associated with natural truncation mutants.
Wong-Mauldin K, Raussens V, Forte TM, Ryan RO., Free PMC Article | 01/25/2010 |
| These findings are consistent with the presence of a functional PPAR-binding element in the promoter of the human APOA5 gene; this element is however degenerate and non-functional in the corresponding mouse Apoa5 sequence. | Differential regulation of the human versus the mouse apolipoprotein AV gene by PPARalpha. Implications for the study of pharmaceutical modifiers of hypertriglyceridemia in mice.
Prieur X, Lesnik P, Moreau M, Rodríguez JC, Doucet C, Chapman MJ, Huby T. | 01/21/2010 |
| Data suggest that higher plasma apolipoprotein AV levels reflect an increased demand for plasma triglyceride hydrolysis under normal physiological conditions. | Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels.
Vaessen SF, Dallinga-Thie GM, Ross CJ, Splint LJ, Castellani LW, Rensen PC, Hayden MR, Schaap FG, Kuivenhoven JA., Free PMC Article | 01/21/2010 |
| the apoCIII enhancer contributes to the maintenance of an active chromatin subdomain of the apoAI/CIII/AIV genes, but not apoAV | The apolipoprotein CIII enhancer regulates both extensive histone modification and intergenic transcription of human apolipoprotein AI/CIII/AIV genes but not apolipoprotein AV.
Li YJ, Wei YS, Fu XH, Hao DL, Xue Z, Gong H, Zhang ZQ, Liu DP, Liang CC., Free PMC Article | 01/21/2010 |
| oxidized fatty acids may act through an APOA5/APOClll mechanism that contributes to lowering of TG levels other than PPAR* induction | Dietary oxidized linoleic acid lowers triglycerides via APOA5/APOClll dependent mechanisms.
Garelnabi M, Selvarajan K, Litvinov D, Santanam N, Parthasarathy S., Free PMC Article | 01/21/2010 |
| and metabolic consequences and phenotype of the three APOA5 mutations reported to date, which lead to premature truncations of apoAV are described | Rare APOA5 mutations--clinical consequences, metabolic and functional effects: an ENID review.
Talmud PJ. | 01/21/2010 |
| These data suggest that in addition to its TG-lowering effect, apoA-V plays a significant role in modulating HDL maturation and cholesterol metabolism. | Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice.
Qu S, Perdomo G, Su D, D'Souza FM, Shachter NS, Dong HH., Free PMC Article | 01/21/2010 |
| apoAV reduces triglyceride levels by guiding VLDL and chylomicrons to proteoglycan-bound LPL for lipolysis | Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase.
Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, Laatsch A, Heeren J. | 01/21/2010 |
| APOA5 could also influence cholesterol homeostasis and probably play a role in hypertriglyceridemia associated with diabetes and inflammation. | Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?
Jakel H, Nowak M, Helleboid-Chapman A, Fruchart-Najib J, Fruchart JC. | 01/21/2010 |
| absence of apoAV slows lipolysis of triglyceride rick lipoprotein and the removal of their remnants by regulating their apoproteins content after secretion | Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants.
Grosskopf I, Baroukh N, Lee SJ, Kamari Y, Harats D, Rubin EM, Pennacchio LA, Cooper AD. | 01/21/2010 |
| in staggerer mice, apoa5 gene is not affected by RORalpha | Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha.
Genoux A, Dehondt H, Helleboid-Chapman A, Duhem C, Hum DW, Martin G, Pennacchio LA, Staels B, Fruchart-Najib J, Fruchart JC. | 01/21/2010 |
| These data demonstrate that (i) apoA-V expression decreases early during the APR due to changes in mRNA stability, and (ii) during the APR apoA-V is not inversely related to plasma TG levels in mice and humans. | Altered apolipoprotein A-V expression during the acute phase response is independent of plasma triglyceride levels in mice and humans.
Becker S, Schomburg L, Renko K, Tölle M, van der Giet M, Tietge UJ. | 01/21/2010 |
| Review. APOA5 represents a newly discovered gene involved in triglyceride metabolism in both humans and mice whose mechanism of action remains to be deciphered. | Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice.
Pennacchio LA, Rubin EM. | 01/21/2010 |